Search Results for "Http Dx Doi Org 10 1002 Adma 201104290"

05:44 EDT 31st March 2015 | BioPortfolio

Matching Channels

Freiberg Infraction

Freiberg's disease is an osteochondrosis of the metatarsal head, most commonly occurring in young athletes older than 12 years who perform on their toes in either sprinting or jumping activities...

Pediculosis - louse (lice) treatment

   To view our most recent articles on Lice Treatment please go to:    

Pediculosis - louse (lice) infestation

   To view our most recent article on Lice Infestation please go to: 

Pediculosis - louse (lice) diagnosis

   To view our most recent articals on Lice Diagnosis please view:

G-protein-coupled receptors (GPCRs)

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers th...

Matching News

Esperion hits record high on ETC-1002 results

Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) jumped $22.50 (29%) to $99.60, hitting an all-time high on Tuesday after the company said ETC-1002 met the primary endpoint of lowering LDL-cholester...

ADMA Biologics, Inc. (Nasdaq:ADMA) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- What:  ADMA Biologics, Inc. (Nasdaq:ADMA), a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based bio...

ADMA Biologics nets $9.2mm via FOPO

Infectious disease-focused ADMA Biologics Inc. netted $9.2mm through the follow-on offering of 1.2mm common shares at $8 each. Proceeds will help fund the anticipated launch of its lead antibody candi...

ADMA Biologics nets $10.6mm via FOPO

Infectious disease-focused ADMA Biologics Inc. netted $10.6mm through the follow-on offering of 1.4mm common shares (including the overallotment) at $8 each. Proceeds will help fund the anticipated la...

Esperion jumps on Phase IIb ETC-1002 results

Esperion Therapeutics Inc. (NASDAQ:ESPR) said both doses of its ETC-1002 met the primary endpoint compared to ezetimibe in a Phase IIb study to treat patients with hypercholesterolemia, with or withou...

ADMA will submit BLA on Phase III RI-002 results

Ramsey, New Jersey-based ADMA Biologics will submit a biologics license application (BLA) to the US FDA during the first half of 2015 based on positive Phase III clinical trial results for RI-002 in t...

ADMA’s lead product meets primary endpoint in Phase III trial

US-based biopharmaceutical company ADMA Biologics says that its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.

Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia

- ETC-1002-008 study meets primary endpoint - - LDL-cholesterol lowering significantly greater with ETC-1002 than ezetimibe - - ETC-1002 appears to be saf...

Matching PubMed Articles

Serum reference intervals of homoarginine, ADMA, and SDMA in the Study of Health in Pomerania.

Abstract Background: Low circulating homoarginine as well as high levels of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have been associated with impaired cardiovascular (...

BLX-1002 restores glucose sensitivity and enhances insulin secretion stimulated by GLP-1 and sulfonylurea in type 2 diabetic pancreatic islets.

BLX-1002 is a novel thiazolidinedione with no peroxisome proliferator-activated receptor (PPAR) activity that has been shown to improve glycemia in type 2 diabetes without weight gain. We previously f...

Plasma Homocysteine and Asymmetrical Dimethyl-l-Arginine (ADMA) and Whole Blood DNA Methylation in Early and Neovascular Age-Related Macular Degeneration: A Pilot Study.

Abstract Purpose/Aim: To compare the plasma levels of homocysteine and asymmetrical dimethyl-l-arginine (ADMA) and the degree of whole blood DNA methylation in patients with early and neovascular age-...

Asymmetric dimethylarginine and L-arginine levels in neonatal sepsis and septic shock.

Abstract Objective: Nitric oxide (NO) formed by the enzyme NO synthase (NOS) from L-arginine, is an important mediator for pathogen elimination. Being a potent vasodilator NO is implicated in hypotens...

Associations of methylarginines and homoarginine with diastolic dysfunction and cardiovascular risk factors in patients with preserved left ventricular ejection fraction.

Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine are considered to modulate nitric oxide synthesis. We evaluated whether ADMA, SDMA and homoarginine are associate...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement